Ultra‐Early Blood Pressure Reduction Attenuates Hematoma Growth and Improves Outcome in Intracerebral Hemorrhage
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objective: The aim was to investigate whether intensive blood pressure treatment is associated with less hematoma growth and better outcome in intracerebral hemorrhage (ICH) patients who received intravenous nicardipine treatment ≤2 hours after onset of symptoms. Methods: A post‐hoc exploratory analysis of the Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 (ATACH‐2) trial was performed. This was a multicenter, international, open‐label, randomized clinical trial, in which patients with primary ICH were allocated to intensive versus standard blood pressure treatment with nicardipine ≤4.5 hours after onset of symptoms. We have included 913 patients with complete imaging and follow‐up data in the present analysis. Results: Among the 913 included patients, 354 (38.7%) had intravenous nicardipine treatment initiated within 2 hours. In this subgroup of patients treated within 2 hours, the frequency of ICH expansion was significantly lower in the intensive blood pressure reduction group compared with the standard treatment group (p = 0.02). Multivariable analysis showed that ultra‐early intensive blood pressure treatment was associated with a decreased risk of hematoma growth (odds ratio, 0.56; 95% confidence interval [CI], 0.34–0.92; p = 0.02), higher rate of functional independence (odds ratio, 2.17; 95% CI, 1.28–3.68; p = 0.004), and good outcome (odds ratio, 1.68; 95% CI, 1.01–2.83; p = 0.048) at 90 days. Ultra‐early intensive blood pressure reduction was associated with a favorable shift in modified Rankin Scale score distribution at 3 months (p = 0.04). Interpretation: In a subgroup of ICH patients with elevated blood pressure given intravenous nicardipine ≤2 hours after onset of symptoms, intensive blood pressure reduction was associated with reduced hematoma growth and improved functional outcome. ANN NEUROL 2020;88:388–395.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Qureshi, A. I., Mendelow, A. D., & Hanley, D. F. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60371-8 · Cited by 1,526
Self-citationEfficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707534 · Cited by 1,255 · cited 1×
“5 hours.(28,29) A large study of reversal of anticoagulation suggested a benefit of intensive BP reduction, plus rapid anticoagulant reversal, only within the first few hours.”
BackgroundKuramatsu, J. B., Gerner, S. T., Schellinger, P. D., Glahn, J., Endres, M., Sobesky, J., Flechsenhar, J., Neugebauer, H., Jüttler, E., Grau, A., et al. (2015) · JAMA · doi:10.1001/jama.2015.0846 · Cited by 568
Cited by
Greenberg, S. M., Ziai, W. C., Cordonnier, C., Dowlatshahi, D., Francis, B., Goldstein, J. N., Hemphill, J. C., Johnson, R., Keigher, K. M., Mack, W. J., et al. (2022) · Stroke · doi:10.1161/str.0000000000000407 · Cited by 1,639
Self-citationHilkens, N. A., Casolla, B., Leung, T. W., & de Leeuw, F.-E. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00642-1 · Cited by 681
Puy, L., Parry-Jones, A. R., Sandset, E. C., Dowlatshahi, D., Ziai, W., & Cordonnier, C. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00424-7 · Cited by 323
Self-citation
Metadata
- Authors
- Li, Q., Warren, A. D., Qureshi, A. I., Morotti, A., Falcone, G. J., Sheth, K. N., Shoamanesh, A., Dowlatshahi, D., Viswanathan, A., & Goldstein, J. N.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2020-07
- Volume
- 88
- Issue
- 2
- Pages
- 388-395
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W3029589626
- Cited by
- 159
- References
- 3
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ultra‐Early Blood Pressure Reduction Attenuates Hematoma Growth and Improves Outcome in Intracerebral Hemorrhage. https://app.cochat.ai/papers/10.1002/ana.25793
- The paper
- Li, Q., Warren, A. D., Qureshi, A. I., Morotti, A., Falcone, G. J., Sheth, K. N., Shoamanesh, A., Dowlatshahi, D., Viswanathan, A., & Goldstein, J. N. (2020). Ultra‐Early Blood Pressure Reduction Attenuates Hematoma Growth and Improves Outcome in Intracerebral Hemorrhage. Annals of Neurology. https://doi.org/10.1002/ana.25793
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.